Skip to content

Study · Randomized controlled trial · n = 147 · 2004

8 results

European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia.

Mansel RE, Goyal A, Preece P, Leinster S, Maddox PR, Gateley C, Kubista E, von Fournier D

American journal of obstetrics and gynecology1 Dec 2004Cited by 27 (Europe PMC)

PMID15592276 (opens in a new tab)DOI10.1016/j.ajog.2004.06.100 (opens in a new tab)PepBankPUB-15592276
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with mastalgia, mean breast pain scores improved by 67% with goserelin versus 35% with sham during treatment.

    In plain wordsIn women with breast pain, pain scores improved by 67% with goserelin versus 35% with sham.

    Peptide
    Goserelin
    Outcome
    Direction not reportedBreast pain during treatment
    Study

    n = 147

    Comparator
    Sham injection
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    3.6 mg/month · 6 monthsAs given in this study (human).

    Measurements

    Pain score improvement
    67%
    goserelin
    Pain score improvement
    35%
    sham

    Source sentences

    Summary
    Mean breast pain score improved by 67% in the goserelin group and 35% in the sham group during the treatment period.
    3 context sentences
    Summary · context
    A significant treatment difference between the 2 groups in favor of goserelin was noted during the treatment period.
    Summary · context
    One hundred forty-seven premenopausal women were randomized to treatment with either goserelin injection (3.6 mg/month) or sham injection for a total of 6 injections.
    Summary · context
    Patients' daily self-assessment of breast pain using Cardiff breast pain chart was recorded during the 6-month treatment period and for 6 months in the posttreatment period.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with mastalgia, posttreatment pain increased in both groups, with no significant difference between goserelin and sham.

    In plain wordsAfter treatment, breast pain increased in both groups, with no significant difference between goserelin and sham.

    Peptide
    Goserelin
    Outcome
    No significant changePosttreatment breast pain
    Study

    n = 147

    Comparator
    Sham injection
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    3.6 mg/month · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    No significant posttreatment difference was found between the two groups.
    3 context sentences
    Summary · context
    The mean pain scores increased in both groups in the posttreatment period.
    Summary · context
    One hundred forty-seven premenopausal women were randomized to treatment with either goserelin injection (3.6 mg/month) or sham injection for a total of 6 injections.
    Summary · context
    Patients' daily self-assessment of breast pain using Cardiff breast pain chart was recorded during the 6-month treatment period and for 6 months in the posttreatment period.
  3. 03HumanRandomized controlled trialSafety outcome

    In women with mastalgia, side effects were more common with goserelin than sham injection.

    In plain wordsIn women with breast pain, side effects were more common with goserelin than sham injection.

    Peptide
    Goserelin
    Outcome
    IncreaseOverall side effects
    Study

    n = 147

    Comparator
    Sham injection
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.6 mg/month · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Side effects were more common with goserelin than sham injection.
    2 context sentences
    Summary · context
    One hundred forty-seven premenopausal women were randomized to treatment with either goserelin injection (3.6 mg/month) or sham injection for a total of 6 injections.
    Summary · context
    Patients' daily self-assessment of breast pain using Cardiff breast pain chart was recorded during the 6-month treatment period and for 6 months in the posttreatment period.
  4. 04HumanRandomized controlled trialSafety outcome

    In women with mastalgia, vaginal dryness occurred more frequently with goserelin than sham.

    In plain wordsIn women with breast pain, vaginal dryness was more common with goserelin than sham.

    Peptide
    Goserelin
    Outcome
    IncreaseVaginal dryness
    Study

    n = 147

    Comparator
    Sham injection
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.6 mg/month · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients receiving goserelin experienced vaginal dryness, hot flushes, decreased libido, oily skin or hair, and a decrease in breast size more frequently than sham patients.
    2 context sentences
    Summary · context
    One hundred forty-seven premenopausal women were randomized to treatment with either goserelin injection (3.6 mg/month) or sham injection for a total of 6 injections.
    Summary · context
    Patients' daily self-assessment of breast pain using Cardiff breast pain chart was recorded during the 6-month treatment period and for 6 months in the posttreatment period.
  5. 05HumanRandomized controlled trialSafety outcome

    In women with mastalgia, hot flushes occurred more frequently with goserelin than sham.

    In plain wordsIn women with breast pain, hot flushes were more common with goserelin than sham.

    Peptide
    Goserelin
    Outcome
    IncreaseHot flushes
    Study

    n = 147

    Comparator
    Sham injection
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.6 mg/month · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients receiving goserelin experienced vaginal dryness, hot flushes, decreased libido, oily skin or hair, and a decrease in breast size more frequently than sham patients.
    2 context sentences
    Summary · context
    One hundred forty-seven premenopausal women were randomized to treatment with either goserelin injection (3.6 mg/month) or sham injection for a total of 6 injections.
    Summary · context
    Patients' daily self-assessment of breast pain using Cardiff breast pain chart was recorded during the 6-month treatment period and for 6 months in the posttreatment period.
  6. 06HumanRandomized controlled trialSafety outcome

    In women with mastalgia, decreased libido occurred more frequently with goserelin than sham.

    In plain wordsIn women with breast pain, reduced sexual desire was more common with goserelin than sham.

    Peptide
    Goserelin
    Outcome
    IncreaseDecreased libido
    Study

    n = 147

    Comparator
    Sham injection
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.6 mg/month · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients receiving goserelin experienced vaginal dryness, hot flushes, decreased libido, oily skin or hair, and a decrease in breast size more frequently than sham patients.
    2 context sentences
    Summary · context
    One hundred forty-seven premenopausal women were randomized to treatment with either goserelin injection (3.6 mg/month) or sham injection for a total of 6 injections.
    Summary · context
    Patients' daily self-assessment of breast pain using Cardiff breast pain chart was recorded during the 6-month treatment period and for 6 months in the posttreatment period.
  7. 07HumanRandomized controlled trialSafety outcome

    In women with mastalgia, oily skin or hair occurred more frequently with goserelin than sham.

    In plain wordsIn women with breast pain, oily skin or hair was more common with goserelin than sham.

    Peptide
    Goserelin
    Outcome
    IncreaseOily skin or hair
    Study

    n = 147

    Comparator
    Sham injection
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    3.6 mg/month · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients receiving goserelin experienced vaginal dryness, hot flushes, decreased libido, oily skin or hair, and a decrease in breast size more frequently than sham patients.
    2 context sentences
    Summary · context
    One hundred forty-seven premenopausal women were randomized to treatment with either goserelin injection (3.6 mg/month) or sham injection for a total of 6 injections.
    Summary · context
    Patients' daily self-assessment of breast pain using Cardiff breast pain chart was recorded during the 6-month treatment period and for 6 months in the posttreatment period.
  8. 08HumanRandomized controlled trialSafety outcome

    In women with mastalgia, decreased breast size occurred more frequently with goserelin than sham.

    In plain wordsIn women with breast pain, reduced breast size was more common with goserelin than sham.

    Peptide
    Goserelin
    Outcome
    IncreaseDecreased breast size
    Study

    n = 147

    Comparator
    Sham injection
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.6 mg/month · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients receiving goserelin experienced vaginal dryness, hot flushes, decreased libido, oily skin or hair, and a decrease in breast size more frequently than sham patients.
    2 context sentences
    Summary · context
    One hundred forty-seven premenopausal women were randomized to treatment with either goserelin injection (3.6 mg/month) or sham injection for a total of 6 injections.
    Summary · context
    Patients' daily self-assessment of breast pain using Cardiff breast pain chart was recorded during the 6-month treatment period and for 6 months in the posttreatment period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.